ILOPROST GIVEN BY NEBULISED SOLUTION AT A DOSE OF 2.5 OR 5 MICROGRAMS INHALED 6 TO 9 TIMES DAILY. DOSES SHOULD BE REDUCED IN PATIENTS WITH HEPATIC OR RENAL IMPAIRMENT.
SHOULD PATIENTS DETERIORATE ON THIS TREATMENT, ALTERNATIVE TREATMENTS SHOULD BE CONSIDERED. SEVERAL PATIENTS WHOSE STATUS DETERIORATED WHILE ON ILOPROST WERE SUCCESSFULLY SWITCHED TO INTRAVENOUS EPOPROSTENOL.
Administration:
VENTAVIS IS INTENDED TO BE INHALED USING EITHER OF TWO PULMONARY DRUG DELIVERY DEVICES: THE I-NEB AAD® SYSTEM OR THE PRODOSE® AAD® SYSTEM. THE 2ML MUST BE USED WITH THE PRODOSE® AAD® SYSTEM AND MAY BE USED WITH THE I-NEB AAD® SYSTEM. THE 1 ML AMPULE DELIVERS 10 MCG TO THE MEDICATION CHAMBER AND MUST ONLY BE USED WITH THE I-NEB™ AAD® SYSTEM.